Literature DB >> 32063037

Regulatory-grade clinical trial design using real-world data.

Mark S Levenson1.   

Abstract

Real-world data and evidence provide the potential to address the effectiveness and safety of drugs. The U.S. Food & Drug Administration has initiated a program to evaluate the potential use of real-world evidence for regulatory uses. Whether a study is designed for regulatory purposes or for other purposes, existing regulation and guidance provide a reference for high-quality studies. Clarifying the study objectives and the role of real-world data in the study are important considerations. Robustness and transparency of the analysis allow for greater understanding and acceptance of the study results.

Entities:  

Keywords:  Evidence; bias; heterogeneity; real-world

Mesh:

Year:  2020        PMID: 32063037      PMCID: PMC8697198          DOI: 10.1177/1740774520905576

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  16 in total

1.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.

Authors:  Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-05       Impact factor: 2.890

2.  The new Sentinel Network--improving the evidence of medical-product safety.

Authors:  Richard Platt; Marcus Wilson; K Arnold Chan; Joshua S Benner; Janet Marchibroda; Mark McClellan
Journal:  N Engl J Med       Date:  2009-07-27       Impact factor: 91.245

3.  Propensity-score-based priors for Bayesian augmented control design.

Authors:  Junjing Lin; Margaret Gamalo-Siebers; Ram Tiwari
Journal:  Pharm Stat       Date:  2018-12-09       Impact factor: 1.894

4.  Good practices for quantitative bias analysis.

Authors:  Timothy L Lash; Matthew P Fox; Richard F MacLehose; George Maldonado; Lawrence C McCandless; Sander Greenland
Journal:  Int J Epidemiol       Date:  2014-07-30       Impact factor: 7.196

5.  Quantitative Bias Analysis in Regulatory Settings.

Authors:  Timothy L Lash; Matthew P Fox; Darryl Cooney; Yun Lu; Richard A Forshee
Journal:  Am J Public Health       Date:  2016-05-19       Impact factor: 9.308

6.  Cautions as Regulators Move to End Exclusive Reliance on Intention to Treat.

Authors:  Miguel A Hernán; Daniel Scharfstein
Journal:  Ann Intern Med       Date:  2018-03-20       Impact factor: 25.391

7.  FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial.

Authors:  Noelle M Cocoros; Sean D Pokorney; Kevin Haynes; Crystal Garcia; Hussein R Al-Khalidi; Sana M Al-Khatib; Patrick Archdeacon; Jennifer C Goldsack; Thomas Harkins; Nancy D Lin; David Martin; Debbe McCall; Vinit Nair; Lauren Parlett; Robert Temple; Cheryl McMahill-Walraven; Christopher B Granger; Richard Platt
Journal:  Clin Trials       Date:  2018-11-16       Impact factor: 2.486

8.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.

Authors:  Edward S Kim; Suanna S Bruinooge; Samantha Roberts; Gwynn Ison; Nancy U Lin; Lia Gore; Thomas S Uldrick; Stuart M Lichtman; Nancy Roach; Julia A Beaver; Rajeshwari Sridhara; Paul J Hesketh; Andrea M Denicoff; Elizabeth Garrett-Mayer; Eric Rubin; Pratik Multani; Tatiana M Prowell; Caroline Schenkel; Marina Kozak; Jeff Allen; Ellen Sigal; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

9.  Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland Coronary Prevention Study.

Authors:  Sarah J E Barry; Eleanor Dinnett; Sharon Kean; Allan Gaw; Ian Ford
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

10.  Development and Validation of a High-Quality Composite Real-World Mortality Endpoint.

Authors:  Melissa D Curtis; Sandra D Griffith; Melisa Tucker; Michael D Taylor; William B Capra; Gillis Carrigan; Ben Holzman; Aracelis Z Torres; Paul You; Brandon Arnieri; Amy P Abernethy
Journal:  Health Serv Res       Date:  2018-05-14       Impact factor: 3.402

View more
  3 in total

Review 1.  Real-World Data as External Controls: Practical Experience from Notable Marketing Applications of New Therapies.

Authors:  Rima Izem; Joan Buenconsejo; Ruthanna Davi; Jingyu Julia Luan; LaRee Tracy; Margaret Gamalo
Journal:  Ther Innov Regul Sci       Date:  2022-06-08       Impact factor: 1.337

2.  Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers.

Authors:  Teresa Magalhães; Ricardo Jorge Dinis-Oliveira; Tiago Taveira-Gomes
Journal:  Int J Environ Res Public Health       Date:  2022-07-08       Impact factor: 4.614

3.  Sex-related differences in spontaneous intracerebral hemorrhage outcomes: A prognostic study based on 111,112 medical records.

Authors:  Jieyi Zhao; Tao Zhang; Hongli Wan; Yang Yu; Jin Wen; Xiaoyu Wang
Journal:  Front Neurol       Date:  2022-09-23       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.